SCHEDULE 13G/A: Janus Henderson Group Discloses 7.4% Stake in Ascendis Pharma A/S

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 7.4% in Ascendis Pharma A/S as of March 31, 2025.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, reported beneficial ownership of 4,497,035 American Depositary Shares (ADS) of Ascendis Pharma A/S.
• This ownership represents 7.4% of Ascendis Pharma A/S's class of securities.
• The filing date for the event requiring this statement was March 31, 2025.
• The shares are held with shared voting power and shared dispositive power.
• The acquisition and holding of these securities are stated to be in the ordinary course of business and not for the purpose of changing or influencing the control of Ascendis Pharma A/S.
• Indirect subsidiaries involved in the beneficial ownership include JHIUS, JHIUKL, and JHIAIFML, which are registered investment advisers.

Sentiment

Score: 5

Explanation: A Schedule 13G is a neutral, factual disclosure of ownership. It does not inherently convey positive or negative sentiment about the issuer's performance, only the reporting entity's investment position.

Positives

• Janus Henderson Group plc maintains a significant stake (7.4%) in Ascendis Pharma A/S, indicating continued investment interest from a major institutional investor.
• The filing confirms the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist stance, which can provide stability.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Ascendis Pharma A/S's future performance or Janus Henderson Group plc's investment strategy beyond the current ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Statement from Kristin Mariani, Head of North America Compliance, CCO of Janus Henderson Group plc)

Industry Context

This filing indicates a significant institutional investment in Ascendis Pharma A/S, a biotechnology company. Such filings are common for large asset managers like Janus Henderson Group plc, reflecting their portfolio allocation strategies within the pharmaceutical and biotechnology sectors. It does not provide specific insights into broader industry trends beyond the fact that Ascendis Pharma A/S is a company of interest to large institutional investors.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure of beneficial ownership by a large institutional investor.
• It does not contain performance metrics or operational results for Ascendis Pharma A/S that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The filing itself adheres to SEC reporting standards for institutional ownership.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.

Next Steps

• Janus Henderson Group plc will continue to file amendments to Schedule 13G if their beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold up or down) or if their investment intent changes from passive to active.

Key Dates

Keywords

Ascendis Pharma A/S, Janus Henderson Group plc, Schedule 13G, SEC filing, American Depositary Shares, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals, Investment Adviser, Passive Investment